SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA

Abstract Treatment options for glioblastoma remain limited, particularly those who are not eligible traditional resection, whether due to lesion location or inability tolerate open craniotomy. Maximal-safe resection followed by radiation with concurrent and adjuvant temozolomide offers the best outcomes patients. Unfortunately, all tumors amenable conventional surgical at time of diagnosis only about 1/3 patients able receive a gross-total 15-25% receiving biopsy only, thus reducing their projected overall survival 9 months. Laser interstitial thermal therapy (LITT) is minimally invasive, cytoreductive tool, that has demonstrated safety as approach treat primary brain tumors. METHODS Data from LAANTERN prospective multicenter registry (NCT02392078) was analyzed determine clinical new recurrent IDH wild-type (N=89). Demographics, intraprocedural data, adverse events, KPS, health-economics, data were prospectively collected then separately newly diagnosed GBM (N=29) (N=60). RESULTS Median overall-survival 9.73 months (95% CI: 5.16, 15.91) median post-procedure 8.97 (6.94, 12.36) post-LITT chemoradiotherapy 16.14 (6.11, reached). The length hospital stay 50 hours 80% discharged home. CONCLUSIONS LITT an effective glioblastoma. Importantly, its use in leads OS similar treated resection. remains important alternative inoperable Enrollment ongoing these cohorts will be revisited continues mature. Benefits beyond cytoreduction also being actively explored.